973 results on '"Clifton-Bligh, Roderick"'
Search Results
2. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
3. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
4. Author response to: OSIN-D-24–00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis
5. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement
6. AFFnet - a deep convolutional neural network for the detection of atypical femur fractures from anteriorposterior radiographs
7. Author Correction: Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment
8. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer
9. Recent progress in molecular classification of phaeochromocytoma and paraganglioma
10. Genotype–Phenotype Correlations and Clinical Outcomes in 155 Cases of Pheochromocytoma and Paraganglioma
11. The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy
12. The Prognostic Impact of Extent of Vascular Invasion in Follicular Thyroid Carcinoma
13. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma
14. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
15. Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience
16. Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment
17. SDHA-related phaeochromocytoma and paraganglioma: review and clinical management.
18. Gene-based association analysis of a large patient cohort provides insights into genetics of atypical femur fractures.
19. Outcomes of SDHB Pathogenic Variant Carriers.
20. The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF: A Systematic Review and Meta-Analysis.
21. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
22. A contemporary clinical approach to genetic testing for heritable hyperparathyroidism syndromes
23. Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy
24. Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment
25. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma
26. Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas
27. Pulmonary BRAF-driven Langerhans cell histiocytosis following selpercatinib use in metastatic medullary thyroid cancer
28. Focused parathyroidectomy without intraoperative parathyroid hormone measurement in primary hyperparathyroidism: Still a valid approach?
29. Tumor-induced osteomalacia – a mystery illness beyond aches, pains, and depression
30. Outcomes of SDHBPathogenic Variant Carriers
31. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
32. Primary hyperparathyroidism in adults—(Part II) surgical management and postoperative follow‐up: Position statement of the Endocrine Society of Australia, The Australian & New Zealand Endocrine Surgeons, and The Australian & New Zealand Bone and Mineral Society
33. Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas.
34. Multikinase inhibitors in thyroid cancer: timing of targeted therapy
35. Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways
36. Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment.
37. Novel prognostic nomogram for predicting recurrence‐free survival in medullary thyroid carcinoma.
38. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
39. Genotype–phenotype correlations in paediatric and adolescent phaeochromocytoma and paraganglioma: a cross-sectional study
40. Checkpoint inhibitor associated autoimmune diabetes mellitus is characterised by C-peptide loss and pancreatic atrophy
41. PAM variants in patients with thyrotrophinomas, cyclical Cushing’s disease and prolactinomas
42. Response to Szymczak et al. re: “A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion”
43. Increased Prevalence of Germline Pathogenic CHEK2Variants in Individuals With Pituitary Adenomas
44. A Preoperative Nomogram for the Prediction of Ipsilateral Central Compartment Lymph Node Metastases in Papillary Thyroid Cancer
45. Genotype--phenotype correlations in paediatric and adolescent phaeochromocytoma and paraganglioma: a cross-sectional study.
46. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
47. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study
48. Development of a novel clinical support tool for active surveillance of low risk papillary thyroid cancer
49. Hypervitaminosis D Secondary to a CYP24A1 Loss‐of‐Function Mutation: An Unusual Cause of Hypercalcemia in Two Siblings
50. The steroid hormone superfamily of receptors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.